Filing Flows › Assembly Biosciences (ASMB) › Q2 2026
Assembly Biosciences (ASMB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Assembly Biosciences (ASMB) reported revenue of $13.4M for the second quarter 2026 (Q2 2026), +39% from a year earlier and +63% from the quarter before. Operating margin was -47.4%, net loss $3.9M (28.8% of revenue).
Assembly Biosciences, Q2 2026: revenue $13.4M (+39% year over year), operating margin -47.4%, net loss $3.9M, operating cash flow −$15.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.4M | +63% | +39% |
| Operating profit | −$6.3M | — | — |
| Net earnings | −$3.9M | — | — |
| Operating cash flow | −$15.5M | — | — |
What changed
Revenue was $13.4M in Q2 2026, up 39% year over year and up 63% from the previous quarter.
Operating costs exceeded revenue by $6.3M, an operating margin of -47.4%. Total costs fell 5% while revenue rose 39%. The quarter ended with a net loss of $3.9M, narrower than the previous quarter's $9.1M loss. Non-operating items added $2.5M, -64% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$15.5M. Non-cash charges added back $20K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $14.1M.
Questions
What was Assembly Biosciences' revenue in the second quarter 2026?
Assembly Biosciences (ASMB) reported revenue of $13.4M for the second quarter 2026 (Q2 2026), +39% from a year earlier and +63% from the quarter before.
Was Assembly Biosciences profitable in the second quarter 2026?
Operating loss was $6.3M (-47.4% of revenue) and net loss $3.9M.